SCHEMBL30866908

SCHEMBL30866908

O=[N+]([O-])c1cc(Br)cnc1OCCCBr

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.34
AKR1B1 P15121 1/20 0.34
CNR2 P34972 1/20 0.33
ERN1 O75460 1/20 0.33
NPC1 O15118 1/20 0.33
RECQL P46063 1/20 0.33
RAB9A P51151 1/20 0.33
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
PKM P14618 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
MAPT P10636 2/20 0.32
LMNA P02545 2/20 0.32
ALDH1A1 P00352 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
PRSS1 P07477 4/20 0.31
S100A4 P26447 1/20 0.31
TRPV1 Q8NER1 1/20 0.31
CYP11B1 P15538 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26131204 1.00 PIN1 (0.34) PIN1AKR1B1CNR2ERN1NPC1
SCHEMBL21494408 0.87 ERN1 (0.35) PIN1AKR1B1CNR2ERN1NPC1
SCHEMBL30866891 0.87 ERN1 (0.35) PIN1AKR1B1CNR2ERN1NPC1
SCHEMBL18760026 0.84 LMNA (0.40) PIN1AKR1B1CNR2NPC1RECQL
SCHEMBL25355126 0.83 KDM4E (0.38) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL29970941 0.83 KDM4E (0.38) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL26131845 0.82 ALDH1A1 (0.41) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL29969078 0.82 ALDH1A1 (0.41) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL858319 0.81 MAPT (0.42) AKR1B1ERN1NPC1RECQLRAB9A
SCHEMBL28526026 0.81 AKR1B1 (0.35) PIN1AKR1B1ERN1NPC1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112469720-B Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy 艾科思莱德制药公司 2024-03-29 CN disclosed